As the debate regarding the administration - intravenous vs. subcutaneous - of Erythropoietin Stimulation Agents (ESA), such as EPOGEN®, continues, it is necessary to ensure that all factors are considered before a decision is made that could adversely affect patients.

Although it has been shown that the volume of ESA’s can be reduced if administered subcutaneously, it is important to look at the impact these changes could have on patients’ quality of care and patients’ quality of life before making comprehensive decisions.

Factors to consider:

• Currently there is no data to prove that receiving subcutaneous ESA’s results in better patient outcomes.
• In addition to the route of administration, there are multiple extenuating factors that influence the dosage and effectiveness of ESA’s.
• Much of Europe has discontinued the administration of ESA’s subcutaneously partially due to Pure Red Cell Aplasia.
• There is not a comprehensive study to assess how receiving ESA’s subcutaneously affects the quality of life of dialysis patients.

DPC welcomes additional research and encourages further patient input on the impact subcutaneous administration of ESA’s will have on patient outcomes and quality of life. We believe that, ultimately, patients should continue to receive the treatments and medications as prescribed by their doctors.